# US 2010/0249414 A1 · Crystalline form ii of 7-(dimethoxy-methyl) camptothecin, its use as intermediate and products obtained therefrom

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0249414 A1
- Document ID: US20100249414A1
- Status: Published application
- Kind: A1
- Application number: 12/670,905
- Filed: 2008-07-22
- Published: 2010-09-30
- Earliest claimed: 2007-08-01
- Assignees: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
- Inventors: Walter Cabri; Mauro Marzi; Fabrizio Giorgi; Elena Badaloni; Silvia Armaroli; Giuseppe Marazzi
- Web page: https://patentgrep.com/patent/US20100249414A1

## CPC

- C07D 491/22: in which the condensed system contains four or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

This invention relates to a process for preparing a crystalline form of (4S)-11-(dimethoxymethyl)-4-ethyl-4-hydroxy-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]qui-noline-3,14(4H,12H)-dione (also named 7-(dimethoxy-methyl)camptothecin). With the provision of a particular crystallization step, in appropriate way, a new crystalline form of the above compound is obtained. The process for the preparation of the polymorph Form II comprises transforming camptothecin to the corresponding 7-(dimethoxy-methyl)-camptothecin, and crystallizing it from methanol.

## Claims

### Claim 1

Polymorph Form II of 7-(dimethoxy-methyl)camptothecin.

### Claim 2 (depends on 1)

The polymorph Form II according to claim 1, which undergoes degradation starting from the temperature of about 160° C.

### Claim 3 (depends on 1)

The polymorph Form II according to claim 1, wherein said polymorph shows an X-ray powder diffraction pattern having the following characteristic peaks expressed in degrees 2Θ±0.2
Degrees 2-Theta
Relative intensity (%)
6.3
20
8.7
21
10.6
100
13.6
23
16.3
18
16.7
20
19.5
13
21.2
21
25.3
22
27.4
17

### Claim 4 (depends on 1)

The polymorph Form II according to claim 1, which shows an X-ray powder diffraction pattern as shown in FIG. 1.

### Claim 5 (depends on 1)

The polymorph Form II according to claim 1, which shows an IR spectrum (KBr) with the following main peaks:
Frequency (cm″1)
Intensity (% T)
3518
53
2989
65
2936
65
1744
21
1660
21
1463
50
1155
31
1060
23
769
37

### Claim 6 (depends on 1)

The polymorph Form II according to claim 1 which shows an IR spectrum as shown in FIG. 2.

### Claim 7 (depends on 1)

The polymorph Form II according to claim 1, which is substantially free from aldehyde impurity.

### Claim 8 (depends on 1)

A solvate of the polymorph Form II of claim 1.

### Claim 9 (depends on 1)

A process for the preparation of the polymorph Form II of claim 1, comprising the following steps:
a. oxidizing position 7 of camptothecin or a derivative thereof to obtain the corresponding 7-keto-camptothecin or 7-keto-camptothecin derivative;
b. treating 7-keto-camptothecin or 7-keto-camptothecin derivative obtained in step a) with methanol, in the presence of an acid to obtain a first, acid methanol reaction mixture;
c. neutralizing said first, acid methanol reaction mixture from step b) to obtain a second, substantially neutral methanol reaction mixture;
d. adding water to said second, substantially neutral methanol reaction mixture, to obtain a precipitate;
e. separating said precipitate of step d) to obtain an isolated precipitate;
f. crystallizing said isolated precipitate of step e) from methanol to give said polymorph.

### Claim 10 (depends on 9)

Process according to claim 9, wherein the oxidizing step of step a) is performed with a first oxidizing system and a second oxidizing system.

### Claim 11 (depends on 10)

Process according to claim 10, wherein said first oxidizing system is 30% H2O2/Fe(II) salt and said second oxidizing system is selected from the group consisting of acetic acid, CrO3, and MnO2.

### Claim 12 (depends on 11)

Process according to claim 11, wherein said first oxidizing system is 30% H2O2/iron sulphate and said second oxidizing system is manganese dioxide.

### Claim 13 (depends on 9)

Process according to claim 9, wherein said first, acid methanol reaction mixture of step b) is selected from the group consisting of distilled methanol and 30% water/70% methanol solution.

### Claim 14 (depends on 9)

Process according to claim 9, wherein said acid of step b is selected from the group consisting of H2SO4, CH3COOH, H3PO4, HCl SOCl2, COCl2, CH3SO2OH, CH3PhSO2OH, CF3COOH, CF3SO3H.

### Claim 15 (depends on 14)

Process according to claim 14, wherein said acid of step b) is 98% H2SO4.

### Claim 16 (depends on 14)

Process according to claim 14, wherein said acid is in a concentration of 10% v/v.

### Claim 17 (depends on 9)

Process according to claim 9, wherein, after step f) said crystallized polymorph Form II is dried under vacuum at 40° C. overnight.

### Claim 18 (depends on 1)

Use of the polymorph Form II of claim 1 in a process for the preparation of a camptothecin derivative.

### Claim 19 (depends on 1)

A process for the preparation of a camptothecin derivative in which the polymorph Form II of claim 1 is used.
